Pharmacyclics’ Ibrutinib Scoops Another FDA Breakthrough Designation, And Pfizer Joins The Club

Pharmacyclics and partner J&J announce a third breakthrough therapy designation from FDA for ibrutinib for hard-to-treat CLL patients with the 17p deletion. Also, NIH investigators report positive Phase II data confirming single-agent activity at the AACR meeting in Washington, D.C.